Compare Novo Nordisk A/S (NVO) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Teucrium Wheat Fund — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Teucrium Wheat Fund trades at $25.21. The key difference: Novo Nordisk A/S pays a 3.63% dividend while Teucrium Wheat Fund pays none, and Teucrium Wheat Fund is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | WEAT | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $71.70 | $25.49 |
52-Week Low | $35.29 | $19.88 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
WEAT trades at $24.99, down 1.03% in the last session, with technical indicators showing a mixed but overall bullish bias. The USDA's reduced 2026 wheat production forecast to 1.56 billion bushels (WSJ, 2026-05-12) and recent wheat price volatility highlight fundamental supply-side influences. Moving averages signal strong bullish momentum, though oscillators indicate near-term overbought conditions.
The outlook for WEAT is cautiously optimistic, driven by agricultural commodity trends and supportive technicals. Key opportunities include exposure to wheat price appreciation, but risks involve weather impacts on crops, inflation fluctuations, and competitive ETF pressure as noted in recent coverage (24/7 Wall Street, 2026-05-16).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
